Hormone Insight

Can a polypill improve heart-failure treatment?

Combining three heart-failure medicines into one daily capsule improved six-month MRI-measured ejection fraction versus actively optimized separate medicines. Secondary clinical-event findings are encouraging but do not establish a mortality benefit.

Randomized trial · Nature Medicine 2026

Reference: Pandey A, Keshvani N, Rizvi SK, et al. Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial. Nat Med. 2026;32:2933–2940. doi:10.1038/s41591-026-04504-5. PMID:42393373.

Chapters

0:00 Intro

0:38 The trial

3:23 My take

4:01 Outro

Read the structured trial summary at hormoneinsight.com

This podcast is intended for healthcare professionals only. It is educational and is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.

AI narration disclosure: This episode uses AI-generated narration.

For healthcare professionals. Educational content only; not medical advice or a substitute for clinical judgement, individual assessment or current guidance.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does tirzepatide improve cardiovascular outcomes and quality of life in patients with heart failure with preserved ejection fraction and obesity?

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide reduced the risk of cardiovascular death or worsening heart failure and improved health status compared with placebo.

Randomized trial · NEJM 2025

Reference: Packer M, Zile MR, Kramer CM. N Engl J Med. 2025; PMID: 39555826

Chapters

0:00 Intro

0:38 The trial

3:27 My take

4:02 Outro

Read the structured trial summary at hormoneinsight.com

This podcast is intended for healthcare professionals only. It is educational and is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.

AI narration disclosure: This episode uses AI-generated narration.

For healthcare professionals. Educational content only; not medical advice or a substitute for clinical judgement, individual assessment or current guidance.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does empagliflozin help patients with chronic kidney disease?

In patients with chronic kidney disease at risk of progression, empagliflozin reduced the risk of kidney-disease progression or cardiovascular death compared with placebo by about 28%.

Randomized trial · NEJM 2023

Reference: The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. The New England journal of medicine. 2023;388(2):117-127. doi:10.1056/NEJMoa2204233. PMID:36331190.

Chapters

0:00 Intro

0:38 The trial

3:33 My take

4:11 Outro

Read the structured trial summary at hormoneinsight.com

This podcast is intended for healthcare professionals only. It is educational and is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.

AI narration disclosure: This episode uses AI-generated narration.

For healthcare professionals. Educational content only; not medical advice or a substitute for clinical judgement, individual assessment or current guidance.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does semaglutide reduce kidney and cardiovascular risks in patients with type 2 diabetes and chronic kidney disease?

In patients with type 2 diabetes and chronic kidney disease, once-weekly semaglutide 1.0 mg reduced the risk of major kidney disease events and death from cardiovascular causes compared with placebo (about 24% lower primary-outcome risk).

Randomized trial · NEJM 2024

Reference: Perkovic V, Tuttle KR, Rossing P. N Engl J Med. 2024; PMID: 38785209.

Chapters

0:00 Intro

0:38 The trial

3:58 My take

4:35 Outro

AI narration disclosure: This episode uses AI-generated narration.

For healthcare professionals. Educational content only; not medical advice or a substitute for clinical judgement, individual assessment or current guidance.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does finerenone slow kidney function loss in adults with chronic kidney disease without diabetes?

In adults with albuminuric CKD without diabetes, finerenone slowed kidney function decline compared with placebo over 32 months, but hyperkalemia was more frequent.

Randomized trial · NEJM 2026

Reference: Heerspink HJL, Neuen BL, Agarwal R, et al. N Engl J Med. 2026;395(6):533-545. doi:10.1056/NEJMoa2604625. PMID:42246672.

Chapters

0:00 Intro

0:38 The trial

3:54 My take

4:38 Outro

AI narration disclosure: This episode uses AI-generated narration.

For healthcare professionals. Educational content only; not medical advice or a substitute for clinical judgement, individual assessment or current guidance.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does once-daily low-dose prednisolone change short-term bone and metabolic outcomes compared with thrice-daily hydrocortisone in adults with established adrenal insufficiency?

This four-minute Hormone Insight briefing examines a 9-month, double-blind, 2-period crossover randomised clinical trial. Forty-seven adults were randomised and 46 analysed; each regimen was given for 120 days with at least a 2-week washout.

Primary findings with prednisolone were lower carboxylated osteocalcin by 1.22 ng/mL (95% CI -2.35 to -0.10; P=.04) and lower undercarboxylated osteocalcin by 1.38 ng/mL (95% CI -2.32 to -0.44; P=.005). Weight, waist circumference, BMI and HbA1c were also lower. Quality of life, lipids, blood pressure and overall adverse-event frequency did not differ significantly.

Safety remains important: 133 adverse events occurred in 37 participants, including 3 serious events; 1 participant withdrew for hyponatraemia, there were 17 stress-related dose-doubling episodes, and no adrenal crises. These are short-term surrogate findings, not proof of fewer fractures, cardiovascular events or deaths.

Limitations include the small single-centre sample, selected adults already established on replacement, 120-day treatment periods and unadjusted secondary P values.

Educational content for doctors and health professionals; not individual treatment advice. Do not change glucocorticoid replacement without specialist review. Narration is AI-generated; no independent human clinical approval is claimed.

Primary report: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2846925

PubMed: https://pubmed.ncbi.nlm.nih.gov/41874506/

Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC13014172/

DOI: 10.1001/jamanetworkopen.2026.2982 | PMID: 41874506

Explore Hormone Insight:

Website: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Hormone Insight examines whether evolocumab reduces first major cardiovascular events in a selected high-risk population without previous myocardial infarction or stroke.

This is an appraisal of the primary VESALIUS-CV randomised trial, not a new study announcement. We cover the two primary composites, absolute benefit, adverse events, the statistical boundary around mortality findings, and clinical applicability.

Key findings:

• 12,257 participants; median follow-up 4.6 years.

• Coronary heart disease death, myocardial infarction or ischaemic stroke: five-year Kaplan–Meier estimates 6.2% versus 8.0%; hazard ratio 0.75 (95% CI 0.65–0.86).

• The 1.8 percentage-point difference corresponds to approximately 18 fewer people per 1,000 experiencing the composite over five years, derived from rounded risk estimates.

• Adding ischaemia-driven arterial revascularisation: 13.4% versus 16.2%; hazard ratio 0.81 (95% CI 0.73–0.89).

• Serious adverse events: 28.2% versus 28.9%; adverse-event treatment discontinuation: 3.3% versus 3.7%. Safety collection did not comprehensively capture minor adverse effects.

Around two thirds already had qualifying atherosclerosis. These results should not be applied indiscriminately to generally healthy adults or everyone with diabetes. Mortality analyses below the failed coronary-death test in the hierarchy remain exploratory. Funded by Amgen; 93% of participants were White. No direct comparison against an active alternative such as ezetimibe.

Primary source

Bohula EA et al. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. New England Journal of Medicine. 2026;394:117–127. Online 8 November 2025; issue 8 January 2026.

Article and supplement: https://www.nejm.org/doi/full/10.1056/NEJMoa2514428

PubMed: https://pubmed.ncbi.nlm.nih.gov/41211925/

Trial registration: https://clinicaltrials.gov/study/NCT03872401

AI-generated narration using an authorised voice. Medical education only, not individual medical advice or accredited CME.

An HbA1c benefit is only one part of a clinical decision. This Hormone Insight evidence review examines the randomized treatment phase of CATALYST: mifepristone in selected adults with difficult-to-control type 2 diabetes and biochemical hypercortisolism.

We review the population and trial design, the 24-week HbA1c and weight results, and findings on blood pressure, hypokalaemia, treatment discontinuation and serious adverse events. We also discuss missing data, secondary-endpoint multiplicity and why the result should not be generalized to everyone with type 2 diabetes.

For doctors and healthcare professionals. Learning objectives: identify the selected population; distinguish the primary HbA1c result from secondary findings; interpret efficacy alongside tolerability, safety and missing-data limitations; and recognize the difference between trial eligibility and the licensed indication.

Chapters

00:00 Benefit and treatment burden

00:23 The clinical question

00:47 Cortisol biology

01:10 Two study phases

01:26 The selected population

02:07 Intervention and comparator

02:40 Endpoints and design

03:13 HbA1c results

04:06 Weight results

04:31 Secondary-endpoint interpretation

04:57 Blood pressure

05:16 Hypokalaemia

05:53 Treatment discontinuation

06:25 Serious adverse events

06:59 Euglycaemic ketoacidosis

07:33 Adrenal insufficiency precautions

07:54 Missing data and appraisal

08:50 Long-term outcomes

09:06 Clinical applicability

09:45 Bottom line

10:23 Sources and scope

Primary paper: DeFronzo et al. Diabetes Care. 2025;48(12):2036–2044. DOI: 10.2337/dc25-1055.

PubMed: https://pubmed.ncbi.nlm.nih.gov/40550011/

Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC12635952/

Korlym prescribing information: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=542f3fae-8bc8-4f00-9228-e4b66c9ad6a9

Educational evidence appraisal, not patient-specific advice or a prescribing protocol. No CME accreditation is claimed. Narration is AI-generated using the Fahad voice. Study findings and prescribing information are distinct; consult current local product information before prescribing.

SOUL is a large randomized trial of oral semaglutide in adults with type 2 diabetes and established cardiovascular or kidney disease. In this Hormone Insight clinical evidence discussion, we cover the five-part PICO, the primary MACE result, absolute event rates, the non-significant kidney secondary outcome, patient selection, and limits of generalization. Fahad narration, clean voice-only production, no music. Primary source: PMID 40162642. DOI 10.1056/NEJMoa2501006. For healthcare professionals. This episode is an evidence discussion, not a substitute for the original paper, product information, local guidance, or individualized clinical judgment.

Can once-weekly semaglutide produce meaningful weight loss in adults with obesity?

In this 2-minute evidence brief, we break down the STEP 1 trial, a randomized double-blind clinical trial published in the New England Journal of Medicine in 2021. The study tested semaglutide 2.4 mg once weekly versus placebo, both with lifestyle intervention, in adults with overweight or obesity but without diabetes.

Covered in this video:

• Why the STEP 1 trial was done
• How the trial was conducted
• Main weight loss results
• Safety and gastrointestinal side effects
• Key clinical takeaway
• 
  

Main result: average body weight decreased by 14.9% with semaglutide versus 2.4% with placebo over 68 weeks.

Citation:

Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.

PMID: 33567185

DOI: 10.1056/NEJMoa2032183

This video is for medical education only and does not replace clinical judgment or individual medical advice.

#Semaglutide #STEP1Trial #ObesityMedicine #GLP1 #MedicalEducation

semaglutide, STEP 1 trial, semaglutide obesity, semaglutide weight loss, Wegovy, GLP-1 receptor agonist, obesity treatment, obesity medicine, clinical trial explained, randomized controlled trial, RCT, NEJM, weight loss medication, semaglutide 2.4 mg, evidence based medicine, medical education, endocrinology, hormone insight, GLP-1 weight loss, obesity pharmacotherapy